Tandem Diabetes Care, Inc.
- Jurisdiction
United States - LEI
549300JEPFOD0K4D3I05 - ISIN
US8753722037 (TNDM )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€956.19M - Gross margin
47.0% - EBIT
-€170.05M - EBIT margin
-17.8% - Net income
-€175.24M - Net margin
-18.3%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Sheridan John F | PRESIDENT & CEO |
|
|
|
|
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Josh Gottheimer | April 10, 2025 | $1.00K–$15.00K |
| Gilbert Cisneros | April 7, 2025 | $1.00K–$15.00K |
| Josh Gottheimer | September 11, 2024 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| James Anderson |
|
|
|
Sell |
| Peter Brown |
|
|
|
Sell |